OPK

OPKO Health, Inc. - 10-Q Summary (Period Ended September 30, 2008)

Business Context and Reporting Period

This is a Quarterly Report on Form 10-Q for OPKO Health, Inc., a specialty healthcare company focused on ophthalmic pharmaceuticals, imaging, and diagnostic systems. The report covers the three and nine months ended September 30, 2008. The company is a non-accelerated filer and is currently in a development stage with a history of operating losses. Key operations include the development of the lead drug candidate bevasiranib and the commercialization of ophthalmic instrumentation acquired through the purchase of Ophthalmic Technologies, Inc. (OTI).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: The company generated $4.05 million in revenue for the quarter, compared to zero in the prior year quarter. This is attributed to resumed international sales of OTI instrumentation products. No U.S. sales occurred due to FDA restrictions.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses increased to $3.72 million (Q3 2008) from $2.72 million (Q3 2007), driven by personnel costs and stock-based compensation. Research and development (R&D) expenses were $4.91 million, compared to a net reversal of expense of $4.50 million in the prior year, which included an $8.1 million reversal of stock-based compensation.
• Acquisition Impact: The 2008 period reflects full consolidation of OTI (acquired Nov 2007). In Q2 2008, the company acquired Vidus Ocular, Inc., resulting in a $1.4 million write-off of in-process R&D.
• Capital Structure: In September 2008, the company raised $15 million via a private placement of common stock. Cash balances decreased from $23.4 million (Dec 31, 2007) to $14.6 million (Sep 30, 2008) due to operating losses and capital expenditures.

Guidance, Outlook, Risks, and Contingencies

• Liquidity Risk: Management explicitly states that cash on hand ($14.6 million) is insufficient to meet anticipated cash requirements for the next 12 months. Additional funding is required in the first half of 2009. Failure to secure funding could force delays in clinical trials or operations.
• Regulatory Status: U.S. sales of OTI devices are suspended pending FDA re-inspection of the Toronto facility following a March 2008 warning letter regarding quality system deficiencies. A re-inspection was anticipated in Q4 2008. The 510(k) submission for the OCT/SLO device remains pending.
• Debt Obligations: The company has a fully utilized $12.0 million line of credit with a related party (The Frost Group). In November 2008 (subsequent event), the maturity was extended to January 2011, and the interest rate increased from 10% to 11%.
• Legal Proceedings: The company is defending against a lawsuit filed by Ophthalmic Imaging Systems (OIS) seeking over $7 million in damages for alleged tortious interference. The company is vigorously defending the claims, and no loss has been accrued as the outcome is undeterminable.
• Outlook: The company expects to incur substantial losses in the foreseeable future as it advances the Phase III clinical trial for bevasiranib and builds commercial infrastructure. Profitability is not expected in the near future.

Investor Verification Checklist

• Cash Runway: Verify the timeline for the required funding in the first half of 2009 and the status of any new capital raising efforts.
• FDA Resolution: Confirm the outcome of the FDA re-inspection of the OTI Toronto facility and the status of the 510(k) clearance for U.S. sales.
• Related Party Transactions: Review the terms of the $12 million line of credit and the $15 million equity investment, both involving The Frost Group (controlled by the CEO/Chairman).
• Legal Exposure: Monitor the status of the OIS litigation and potential indemnification obligations.
• Bevasiranib Progress: Track the enrollment and data readouts of the ongoing Phase III clinical trial, which is the primary driver of R&D spend.